Skip to navigation Skip to content

Clinical Trial: Ocrelizumab in Black Americans and Hispanic/Latinx with Relapsing MS

Share

Details
Type of MS: RRMS|SPMS
Treatment mode of action: To stop progression
Number of Subjects: 150
Medication: ocrelizumab
Location: Arizona|California|District of Columbia|Florida|Georgia|Illinois|Indiana|Maryland|Michigan|Missouri|New Jersey|New York|North Carolina|Ohio|Oregon|Pennsylvania|Tennessee|Texas|Virginia|Washington|Wisconsin
Institutions: Multicenter, nationwide Contact Information
https://chimesstudy.com/
888-662-6728

Funding:

Genentech, Inc.

Description

Investigators are recruiting 150 Black Americans and Hispanic/Latinx with relapsing MS to determine the effectiveness of Ocrevus® (ocrelizumab) in these groups. The study, sponsored by Genentech, Inc., also is known as the CHIMES study.

Read more

Share


© 2022 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.